The current pipeline of investigational, muscle-preserving therapies comprises 32 assets, of which 47% are at preclinical stage, 22% in phase 1 and 31% in phase 2, as the most advanced candidates
Advantage : MET-097i Summary and Verdict# MET-097i represents a potentially disruptive approach to GLP-1 therapy with its ultra-long half-life enabling once-monthly dosing
In the univariable analysis, C5-OH less than 0.22 mol/L was negatively associated with CVD in T2DM, utilizing 0.220.30 mol/L as the reference [OR (95%CI) of C5-OH for 3.0.Co;2-s 18 HouQGuanYYuWLiuXWuLXiaoMet al
Current clinical evidence does not clearly establish GLP-1 agonists as a direct cause of kidney stones
Gut integrity, which is a big problem in the endometriosis community
It some cases, it may cause increased blood pressure and lowered heart rate